삼성서울병원

Ko En

Hematology-Oncology Jang, Jun Ho M.D

Expertise
Aplastic anemia, ITP, myelodysplastic syndrome, acute leukemia, MPN
Treament Schedule 12 月
DATE
SUN
01
MON
02
TUE
03
WEB
04
THU
05
FRI
06
SAT
07
SUN
08
MON
09
TUE
10
WEB
11
THU
12
FRI
13
SAT
14
SUN
15
MON
16
TUE
17
WEB
18
THU
19
FRI
20
SAT
21
SUN
22
MON
23
TUE
24
WEB
25
THU
26
FRI
27
SAT
28
SUN
29
MON
30
TUE
31
AM
PM
Treament Schedule 01 月
DATE
WEB
01
THU
02
FRI
03
SAT
04
SUN
05
MON
06
TUE
07
WEB
08
THU
09
FRI
10
SAT
11
SUN
12
MON
13
TUE
14
WEB
15
THU
16
FRI
17
SAT
18
SUN
19
MON
20
TUE
21
WEB
22
THU
23
FRI
24
SAT
25
SUN
26
MON
27
TUE
28
WEB
29
THU
30
FRI
31
AM
PM

Medical Education

2000~2002 Ph.D. in Medicine Graduate School, Yonsei University, Korea
1998~2000 Master of Science Graduate School, Yonsei University, Korea
1986~1992 College of Medicine, Yonsei University, Korea

Post-Graduate Training

Fellowship   2002~2004 University of Michigan Ann Arbor, USA
2000~2002 Hematology-Oncology, Severance Hospital, College of Medicine Yonsei University, Korea
Residency   1999~2002 Internal Medicine, Severance Hospital, College of Medicine Yonsei University, Korea
Internship   1995~1996 Severance Hospital, College of Medicine Yonsei University, Korea

Professional Appointments

2014~present Professor Division of Hematology-Oncology, Sungkyunkwan University School of Medicine, Samsung Medical Center
2013~2015 Chief Division of Hematology-Oncology, Samsung Medical Center
2007~2013 Associate Professor Division of Hematology-Oncology, Sungkyunkwan University School of Medicine, Samsung Medical Center
2004~2007 Clinical Instructor Department of Hematology-Oncology, Ajou University School of Medicine, Suwon, Korea

Professional Memberships

2022~Present Director The Korean Society of blood transfusion
2019~Present Chairman of the commission The Korean Society of Hematology aplastic anemia working Party
2014~Present Director The Korean Society for patient blood management
2010~Present Member The Korean Association of internal medicine
2007~Present Member The Korean Society of Blood and marrow transplantation
1998~Present Member The Korean Society of Hematology
2000~Present Member The American Society of Hematology
2000~Present Member The European Hematology Association

Selected Publications

  • TRANSPL INFECT DIS 2024 10.1111/tid.14328 QuantiFERON monitor predicts early cytomegalovirus infection and viral burden in allogeneic hematopoietic stem cell transplantation Yoon, E; Shin, S; Choi, S; Jang, JH; Kim, K; Kim, SJ; Kim, WS; Jung, CW; Kang, ES
    View PubMed
  • AM J HEMATOL 2024 10.1002/ajh.27412 Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition Röth, A; He, GS; Tong, HY; Lin, ZH; Wang, XQ; Chai-Adisaksopha, C; Lee, JH; Brodsky, A; Hantaweepant, C; Dumagay, TE; Demichelis-Gómez, R; Rojnuckarin, P; Sun, J; Höglund, M; Jang, JH; Gaya, A; Silva, F; Obara, N; Kelly, RJ; Beveridge, L; Buatois, S; Chebon, S; Gentile, B; Lundberg, P; Sreckovic, S; Nishimura, JI; Risitano, A; Han, B
    View PubMed
  • SCI REP-UK 2024 10.1038/s41598-024-57295-5 Validation of the 2022 European LeukemiaNet risk stratification for acute myeloid leukemia Song, GY; Kim, HJ; Kim, T; Ahn, SY; Jung, SH; Kim, M; Yang, DH; Lee, JJ; Kim, MY; Cheong, JW; Jung, CW; Jang, JH; Kim, HJ; Moon, JH; Sohn, SK; Won, JH; Park, SK; Kim, SH; Choi, CK; Kim, HJ; Ahn, JS; Kim, DDH
    View PubMed
  • NEW ENGL J MED 2024 10.1056/NEJMoa2308695 Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria de Latour, RP; Röth, A; Kulasekararaj, AG; Han, B; Scheinberg, P; Maciejewski, JP; Ueda, Y; de Castro, CM; Di Bona, E; Fu, R; Zhang, L; Griffin, M; Langemeijer, SMC; Panse, J; Schrezenmeier, H; Barcellini, W; Mauad, VAQ; Schafhausen, P; Tavitian, S; Beggiato, E; Chew, LP; Gaya, A; Huang, WH; Jang, JH; Kitawaki, T; Kutlar, A; Notaro, R; Pullarkat, V; Schubert, J; Terriou, L; Uchiyama, M; Lee, LWL; Yap, ES; de Fontbrune, FS; Marano, L; Alashkar, F; Gandhi, S; Trikha, R; Yang, C; Liu, H; Kelly, RJ; Höchsmann, B; Kerloeguen, C; Banerjee, P; Levitch, R; Kumar, R; Wang, ZX; Thorburn, C; Maitra, S; Li, SJ; Verles, A; Dahlke, M; Risitano, AM
    View PubMed
  • J KOREAN MED SCI 2024 10.3346/jkms.2024.39.e81 Impact of Lactate Dehydrogenase and Hemoglobin Levels on Clinical Outcomes in Patients With Paroxysmal Nocturnal Hemoglobinuria: Results From the National Korean PNH Registry Jang, JH; Kim, JS; Lim, CTK; Kleinman, NJ; Myren, KJ; Wang, A; Patel, Y; Lee, JW
    View PubMed
  • BLOOD ADV 2024 10.1182/bloodadvances.2023010959 Long-term ef fi cacy and safety of romiplostim in refractory aplastic anemia: follow-up of a phase 2/3 study Mitani, K; Lee, JW; Jang, JH; Tomiyama, Y; Miyazaki, K; Nagafuji, K; Usuki, K; Uoshima, N; Fujisaki, T; Kosugi, H; Matsumura, I; Sasaki, K; Kizaki, M; Sawa, M; Hidaka, M; Kobayashi, N; Ichikawa, S; Yonemura, Y; Murotani, K; Shimizu, M; Matsuda, A; Ozawa, K; Nakao, S
    View PubMed
  • LANCET HAEMATOL 2024 10.1016/S2352-3026(23)00395-2 Activity and safety of eltrombopag in combination with cyclosporin A as first-line treatment of adults with severe aplastic anaemia (SOAR): a phase 2, single-arm study Scheinberg, P; Finelli, C; Montano-Figueroa, EH; Vallejo, C; Norasetthada, L; Calado, RT; Turgut, M; Latour, RPD; Kriemler-Krahn, U; Haenig, J; Clark, J; Jang, J
    View PubMed
  • J KOREAN MED SCI 2023 10.3346/jkms.2023.38.e328 Long-Term Efficacy and Safety of Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria and High Disease Burden: Real-World Data From Korea Kim, JS; Jang, JH; Jo, DY; Ahn, SY; Yoon, SS; Lee, JH; Kim, SH; Choi, CW; Shin, HJ; Kim, MK; Lee, JH; Mun, YC; Kong, JH; Hyun, B; Nam, H; Kim, E; Kwak, MJ; Won, YK; Lee, JW
    View PubMed
  • BLOOD ADV 2023 10.1182/bloodadvances.2022008287 Eltrombopag in patients with chronic immune thrombocytopenia in Asia-Pacific, the Middle East, and Turkey: final analysis of CITE Wong, RSM; Yavasoglu, I; Yassin, MA; Tarkun, P; Yoon, SS; Wei, X; Elghandour, A; Angchaisuksiri, P; Ozcan, M; Yang, RC; Mattar, M; Rahman, M; Ingles, S; Goldbrunner, M; Frueh, JA; Jang, JH
    View PubMed
  • CANCER RES TREAT 2023 10.4143/crt.2022.1407 Clinical Significance of bZIP In-Frame CEBPA-Mutated Normal Karyotype Acute Myeloid Leukemia Ahn, SY; Kim, T; Kim, M; Song, GY; Jung, SH; Yang, DH; Lee, JJ; Kim, MY; Jung, CW; Jang, JH; Kim, HJ; Moon, JH; Sohn, SK; Won, JH; Kim, SH; Kim, HJ; Ahn, JS; Kim, DDH
    View PubMed
  • HAEMATOLOGICA 2023 10.3324/haematol.2022.281562 Biosimilars in rare diseases : a focus on paroxysmal nocturnal hemoglobinuria Kulasekararaj, A; Brodsky, R; Kulagin, A; Jang, JH
    View PubMed
  • AM J HEMATOL 2023 10.1002/ajh.26847 Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial Wei, AH; Dohner, H; Sayar, H; Ravandi, F; Montesinos, P; Dombret, H; Selleslag, D; Porkka, K; Jang, JH; Skikne, B; Beach, CL; Prebet, T; Zhang, GR; Risueno, A; Ugidos, M; See, WL; Menezes, D; Roboz, GJ
    View PubMed
  • DIAGNOSTICS 2022 10.3390/diagnostics12112570 Effects of CALR-Mutant Type and Burden on the Phenotype of Myeloproliferative Neoplasms Kim, HY; Han, Y; Jang, JH; Jung, CW; Kim, SH; Kim, HJ
    View PubMed
  • AM J HEMATOL 2022 10.1002/ajh.26707 Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-A study Jonas, BA; DiNardo, C; Fracchiolla, N; Pristupa, A; Ishizawa, K; Jin, J; Konopleva, M; Ofran, Y; Montesinos, P; Kovacsovics, T; Jang, JH; Kantarjian, H; Duan, YH; Potluri, J; Werner, M; Pratz, KW
    View PubMed
  • BONE MARROW TRANSPL 2022 10.1038/s41409-022-01817-0 Allogeneic hematopoietic cell transplantation can overcome the adverse prognosis indicated by secondary-type mutations in de novo acute myeloid leukemia Song, GY; Kim, T; Ahn, SY; Jung, SH; Kim, M; Yang, DH; Lee, JJ; Choi, SH; Kim, MY; Jung, CW; Jang, JH; Kim, HJ; Moon, JH; Sohn, SK; Won, JH; Park, SK; Kim, SH; Zhang, ZL; Ahn, JS; Kim, HJ; Kim, DDH
    View PubMed
  • BLOOD ADV 2022 10.1182/bloodadvances.2022006960 Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study Jang, JH; Wong, L; Ko, BS; Yoon, SS; Li, K; Baltcheva, I; Nidamarthy, PK; Chawla, R; Junge, G; Yap, ES
    View PubMed
  • AM J HEMATOL 2022 10.1002/ajh.26600 Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia Jonas, BA; Wei, AH; Recher, C; DiNardo, CD; Jang, JH; Pratz, K; Panayiotidis, P; Montesinos, P; Yeh, SP; Ivanov, V; Fiedler, W; Yamauchi, T; Duan, YH; Mendes, W; Potluri, J; Tews, B; Ofran, Y
    View PubMed
  • J CLIN ONCOL 2022 10.1200/JCO.21.01546 Measurable Residual Disease Response and Prognosis in Treatment-Naive Acute Myeloid Leukemia With Venetoclax and Azacitidine Pratz, KW; Jonas, BA; Pullarkat, V; Recher, C; Schuh, AC; Thirman, MJ; Garcia, JS; DiNardo, CD; Vorobyev, V; Fracchiolla, NS; Yeh, SP; Jang, JH; Ozcan, M; Yamamoto, K; Illes, A; Zhou, Y; Dail, M; Chyla, B; Potluri, J; Dohner, H
    View PubMed
  • HAEMATOLOGICA 2021 10.3324/haematol.2021.279174 Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase III, placebo-controlled QUAZAR AML-001 trial Roboz, GJ; Dohner, H; Pocock, C; Dombret, H; Ravandi, F; Jang, JH; Selleslag, D; Mayer, JR; Martens, UM; Liesveld, J; Bernal, T; Wang, MC; Yu, PW; Shi, L; Guo, S; La Torre, I; Skikne, B; Dong, Q; Braverman, J; Nehme, SA; Beach, CL; Wei, AH
    View PubMed
  • ESMO OPEN 2021 10.1016/j.esmoop.2021.100236 Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus paclitaxel plus gemcitabine (KCSG-BR-13-11) Cho, EH; Kim, JY; Im, SA; Jung, KH; Sohn, J; Lee, KS; Chae, YS; Lee, KH; Kim, JH; Jang, JH; Ahn, JH; Park, MS; Lee, SY; Park, YH
    View PubMed
  • J CLIN APHERESIS 2021 10.1002/jca.21924 Correlation between peripheral blood automated hematopoietic progenitor cell counts and flow cytometric CD34(+) cell counts differs according to diagnosis in patients undergoing autologous peripheral blood stem cell transplantation Kim, SM; Kim, HY; Kim, SJ; Jang, JH; Kim, K; Kim, WS; Jung, CW; Cho, D; Kang, ES
    View PubMed
  • ASIA-PAC J CLIN ONCO 2021 10.1111/ajco.13609 Efficacy and safety of blinatumomab: Post hoc pooled analysis in Asian adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia Kobayashi1, Y; Oh, I; Miyamoto, T; Lee, WS; Iida, H; Minami, H; Maeda, Y; Jang, JH; Yoon, SS; Yeh, SP; Tran, Q; Morris, J; Franklin, J; Kiyoi, H
    View PubMed
  • ANN LAB MED 2021 10.3343/alm.2021.41.3.342 LSAMP Rearrangement in Acute Myeloid Leukemia With a Jumping Translocation Involving 3q13.31 Yoon1, J; Cho, EH; Yun, JW; Kim, HY; Jang, JH; Kim, HJ; Kim, SH
    View PubMed
  • KOREAN J INTERN MED 2021 10.3904/kjim.2019.385 Mutations in genes affecting DNA methylation enhances responses to decitabine in patients with myelodysplastic syndrome Jung1, HA; Jung, CW; Jang, JH
    View PubMed
  • J CLIN ONCOL 2021 10.1200/JCO.20.01895 Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study Steensma1, DP; Fenaux, P; Van Eygen, K; Raza, A; Santini, V; Germing, U; Font, P; Diez-Campelo, M; Thepot, S; Vellenga, E; Patnaik, MM; Jang, JH; Varsos, H; Bussolari, J; Rose, E; Sherman, L; Sun, LB; Wan, Y; Dougherty, S; Huang, F; Feller, F; Rizo, A; Platzbecker, U
    View PubMed
  • BRIT J HAEMATOL 2021 10.1111/bjh.17190 Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II/III, multicentre, open-label study Jang1, JH; Tomiyama, Y; Miyazaki, K; Nagafuji, K; Usuki, K; Uoshima, N; Fujisaki, T; Kosugi, H; Matsumura, I; Sasaki, K; Kizaki, M; Sawa, M; Hidaka, M; Kobayashi, N; Ichikawa, S; Yonemura, Y; Enokitani, K; Matsuda, A; Ozawa, K; Mitani, K; Lee, JW; Nakao, S
    View PubMed
  • NEW ENGL J MED 2020 10.1056/NEJMoa2004444 Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission Wei1, AH; Dohner, H; Pocock, C; Montesinos, P; Afanasyev, B; Dombret, H; Ravandi, F; Sayar, H; Jang, JH; Porkka, K; Selleslag, D; Sandhu, I; Turgut, M; Giai, V; Ofran, Y; Cakar, MK; de Sousa, AB; Rybka, J; Frairia, C; Borin, L; Beltrami, G; Cermak, J; Ossenkoppele, GJ; La Torre, I; Skikne, B; Kumar, K; Dong, Q; Beach, CL; Roboz, GJ
    View PubMed
  • SUPPORT CARE CANCER 2020 10.1007/s00520-020-05884-1 Association between body image dissatisfaction and poor quality of life and depression among patients with hematopoietic stem cell transplantation Kang1, D; Kim, IR; Choi, HJ; Jung, CW; Yoon, SS; Kim, JS; Lee, CH; Jang, JH; Cho, J
    View PubMed
  • NEW ENGL J MED 2020 10.1056/NEJMoa2012971 Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia DiNardo1, CD; Jonas, BA; Pullarkat, V; Thirman, MJ; Garcia, JS; Wei, AH; Konopleva, M; Dohner, H; Letai, A; Fenaux, P; Koller, E; Havelange, V; Leber, B; Esteve, J; Wang, J; Pejsa, V; Hajek, R; Porkka, K; Illes, A; Lavie, D; Lemoli, RM; Yamamoto, K; Yoon, SS; Jang, JH; Yeh, SP; Turgut, M; Hong, WJ; Zhou, Y; Potluri, J; Pratz, KW
    View PubMed
  • BRIT J HAEMATOL 2020 10.1111/bjh.16711 Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies de Latour1, RP; Brodsky, RA; Ortiz, S; Risitano, AM; Jang, JH; Hillmen, P; Kulagin, AD; Kulasekararaj, AG; Rottinghaus, ST; Aguzzi, R; Gao, X; Wells, RA; Szer, J
    View PubMed
  • ANTIMICROB AGENTS CH 2020 10.1128/AAC.02467-19 Phase 2 Study of Anti-Human Cytomegalovirus Monoclonal Antibodies for Prophylaxis in Hematopoietic Cell Transplantation Maertens1, J; Logan, AC; Jang, J; Long, G; Tang, JL; Hwang, WYK; Koh, LP; Chemaly, R; Gerbitz, A; Winkler, J; Yeh, SP; Hiemenz, J; Christoph, S; Lee, DG; Wang, PN; Holler, E; Mielke, S; Akard, L; Yeo, A; Ramachandra, S; Smith, K; Pertel, P; Segal, F
    View PubMed
  • ANN LAB MED 2020 10.3343/alm.2020.40.1.88 Relationship of Circulating Cytomegalovirus Levels Obtained Through Antigenemia Testing and Quantitative PCR Differs Between Children and Adults Choi1, S; Kim, YJ; Yoo, KH; Sung, KW; Koo, HH; Kim, SJ; Jang, JH; Kim, K; Jung, CW; Huh, HJ; Kang, ES
    View PubMed
  • MOL BIOL REP 2019 10.1007/s11033-019-05019-8 Anti-leukemic effects of simvastatin on NRAS(G12D) mutant acute myeloid leukemia cells Jang1, J; Lee, J; Jang, JH; Jung, CW; Park, S
    View PubMed
  • Lancet Haematol 2019 10.1016/S2352-3026(19)30153-X Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial Lee1, JW; Lee, SE; Jung, CW; Park, S; Keta, H; Park, SK; Kim, JA; Oh, IH; Jang, JH
    View PubMed
  • INT J HEMATOL 2019 10.1007/s12185-019-02699-7 Comparative study on baseline clinical characteristics of Asian versus non-Asian patients with paroxysmal nocturnal hemoglobinuria Sakurai1, M; Jang, JH; Chou, WC; Kim, JS; Wilson, A; Nishimura, J; Chiou, TJ; Kanakura, Y; Lee, JW; Okamoto, S
    View PubMed
  • BRIT J HAEMATOL 2019 10.1111/bjh.16055 Prospective randomized trial comparing two doses of rabbit anti-thymocyte globulin in patients with severe aplastic anaemia Narita1, A; Zhu, XF; Muramatsu, H; Chen, XJ; Guo, Y; Yang, WY; Zhang, JL; Liu, F; Jang, JH; Kook, H; Kim, H; Usuki, K; Yamazaki, H; Takahashi, Y; Nakao, S; Lee, JW; Kojima, S
    View PubMed
  • CLIN LYMPHOMA MYELOMA LEUK 2019 10.1016/j.clml.2019.06.003 Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System Jung1, KS; Kim, YJ; Kim, YK; Park, SK; Kim, HG; Kim, SJ; Park, J; Choi, CW; Do, YR; Kim, I; Park, S; Mun, YC; Jeong, SH; Kim, MK; Yi, HG; Chang, MH; Kim, SY; Lee, JH; Jang, JH
    View PubMed
  • ANN HEMATOL 2019 10.1007/s00277-019-03735-6 Clinical implication of renal dysfunction during the clinical course in patients with paroxysmal nocturnal hemoglobinuria: a longitudinal analysis Kim1, JS; Cheong, JW; Mun, YC; Jang, JH; Jo, DY; Lee, JW
    View PubMed
  • ANN HEMATOL 2019 10.1007/s00277-019-03624-y Different prognostic effects of core-binding factor positive AML with Korean AML registry data Shin1, HJ; Min, WS; Min, YH; Cheong, JW; Lee, JH; Kim, IH; Hong, DS; Ahn, JS; Kim, HJ; Lee, WS; Jung, CW; Jang, JH; Park, Y; Kim, HJ
    View PubMed
  • Lancet Haematol 2019 10.1016/S2352-3026(18)30231-X Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study Frey1, N; Jang, JH; Szer, J; Illes, A; Kim, HJ; Ram, R; Chong, BH; Rowe, JM; Borisenkova, E; Liesveld, J; Winer, ES; Cherfi, A; Aslanis, V; Ghaznawi, F; Strickland, S
    View PubMed
  • ANN HEMATOL 2019 10.1007/s00277-018-3550-z Utility of allogeneic hematopoietic stem cell transplantation using international donors in a homogenous ethnic population: question in the era of various alternative donors Kim1, SA; Lee, J; Moon, JH; Lee, H; Jang, J; Cheong, JW; Youk, J; Choi, Y; Kang, M; Shin, M; Koh, Y; Shin, S
    View PubMed
  • AM J HEMATOL 2019 10.1002/ajh.25334 Effectiveness of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) with or without aplastic anemia in the International PNH Registry Lee1, JW; de Latour, RP; Brodsky, RA; Jang, JH; Hill, A; Roth, A; Schrezenmeier, H; Wilson, A; Marantz, JL; Maciejewski, JP
    View PubMed
  • ANN LAB MED 2018 10.3343/alm.2018.38.6.495 Poor Prognostic Implication of ASXL1 Mutations in Korean Patients With Chronic Myelomonocytic Leukemia Kim1, HY; Lee, KO; Park, S; Jang, JH; Jung, CW; Kim, SH; Kim, HJ
    View PubMed
  • BONE MARROW TRANSPL 2018 10.1038/s41409-018-0097-5 Satisfaction with sexual activity and sexual dysfunction in hematopoietic stem cell transplantation survivors and their partners: a couple study Yoo1, KH; Kang, D; Kim, IR; Choi, EK; Kim, JS; Yoon, SS; Lee, CH; Park, S; Kim, SJ; Kim, K; Kim, WS; Jung, CW; Choi, HJ; Jang, JH; Cho, J
    View PubMed
  • LEUKEMIA RES 2018 10.1016/j.leukres.2018.04.002 Which donor is better when a matched donor is not available domestically? Comparison of outcomes of allogeneic stem cell transplantation with haploidentical and international donors in a homogenous ethnic population Park1, H; Lee, YJ; Shin, SJ; Lee, J; Park, S; Kim, I; Moon, JH; Lee, H; Jang, JH; Yoon, SS; Koh, Y
    View PubMed
  • ONCOTARGET 2018 10.18632/oncotarget.23575 Assessment of a new genomic classification system in acute myeloid leukemia with a normal karyotype Ahn1, JS; Kim, HJ; Kim, YK; Lee, SS; Ahn, SY; Jung, SH; Yang, DH; Lee, JJ; Park, HJ; Lee, JY; Choi, SH; Jung, CW; Jang, JH; Kim, HJ; Moon, JH; Sohn, SK; Lee, YJ; Won, JH; Kim, SH; Zhang, ZL; Kim, T; Kim, DDH
    View PubMed
  • BMC CANCER 2017 10.1186/s12885-017-3803-6 Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens Seymour1, JF; Dohner, H; Butrym, A; Wierzbowska, A; Selleslag, D; Jang, JH; Kumar, R; Cavenagh, J; Schuh, AC; Candoni, A; Recher, C; Sandhu, I; del Castillo, TB; Al-Ali, HK; Falantes, J; Stone, RM; Minden, MD; Weaver, J; Songer, S; Beach, CL; Dombret, H
    View PubMed
  • J INFECT CHEMOTHER 2017 10.1016/j.jiac.2017.04.004 Atypical presentations of MERS-CoV infection in immunocompromised hosts Kim1, SH; Ko, JH; Park, GE; Cho, SY; Ha, YE; Kang, JM; Kim, YJ; Huh, HJ; Ki, CS; Jeong, BH; Park, J; Jang, JH; Kim, WS; Kang, CI; Chung, DR; Song, JH; Peck, KR
    View PubMed
  • BIOL BLOOD MARROW TR 2017 10.1016/j.bbmt.2017.06.012 Epidemiology and Risk Factors for Invasive Fungal Diseases among Allogeneic Hematopoietic Stem Cell Transplant Recipients in Korea: Results of "RISK" Study Choi1, JK; Cho, SY; Yoon, SS; Moon, JH; Kim, SH; Lee, JH; Kim, JS; Cheong, JW; Jang, JH; Seo, BJ; Kim, YJ; Lee, HJ; Lee, J; Lee, JW; Lee, DG
    View PubMed
  • Nutrition. 2017 Apr;36:67-71. doi: 10.1016/j.nut.2016.06.009. Epub 2016 Jun 25. Patient-Generated Subjective Global Assessment as a prognosis tool in patients with multiple myeloma Kim HS11, Lee JY2, Lim SH2, Cho J3, Kim SJ2, Jang JH2, Kim WS2, Jung CW2, Kim K4.
    View PubMed
  • Oncotarget. 2017 Jan 31;8(5):8305-8314. doi: 10.18632/oncotarget.14171. 5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia Ahn JS11,2, Kim HJ1,2, Kim YK1,2, Lee SS1, Ahn SY1, Jung SH1, Yang DH1, Lee JJ1, Park HJ2, Choi SH2, Jung CW3, Jang JH3, Kim HJ4, Moon JH5, Sohn SK5, Won JH6, Kim SH7, Michael S8, Minden MD9, Kim DD9.
    View PubMed
  • J Infect. 2016 Nov;73(5):496-505. doi: 10.1016/j.jinf.2016.06.011. Epub 2016 Jul 7. Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients Park S11, Kim K1, Jang JH1, Kim SJ1, Kim WS1, Chung DR2, Kang CI2, Peck KR2, Jung CW3.
    View PubMed
  • Oncotarget. 2016 Sep 13;7(37):59892-59901. doi: 10.18632/oncotarget.10988. Blood concentration of cyclosporine during early post-transplant period may have influence on the occurrence of chronic graft versus host disease in patients who received allogeneic hematopoietic stem cell transplantation Park S11, Kim K1, Jang JH1, Kim SJ1, Kim WS1, Jung CW1.
    View PubMed
  • J Clin Pathol. 2016 Aug;69(8):737-41. doi: 10.1136/jclinpath-2016-203649. Epub 2016 May 19. High frequency of JAK2 exon 12 mutations in Korean patients with polycythaemia vera: novel mutations and clinical significance Park CH11, Lee KO2, Jang JH3, Jung CW3, Kim JW1, Kim SH1, Kim HJ1.
    View PubMed
  • Ann Hematol. 2016 Aug;95(8):1223-32. doi: 10.1007/s00277-016-2691-1. Epub 2016 May 26. Cytogenetic profiles of 2806 patients with acute myeloid leukemia-a retrospective multicenter nationwide study Byun JM11, Kim YJ2, Yoon HJ3, Kim SY3, Kim HJ4, Yoon J4, Min YH5, Cheong JW5, Park J6, Lee JH6, Hong DS7, Park SK7, Kim HJ8, Ahn JS8, Shin HJ9, Chung JS9, Lee WS10, Lee SM10, Park Y11, Kim BS11, Lee JH12, Lee KH12, Jung CW13, Jang JH13, Min WS14, Park TS15; AML/MDS working party of Korean Society of Hematology.
    View PubMed
  • Qual Life Res. 2016 Apr;25(4):881-90. doi: 10.1007/s11136-015-1121-5. Epub 2015 Sep 5. Psychometric analysis of the Korean version of the high-dose chemotherapy specific quality of life questionnaire module from the European Organization for Research and Treatment of Cancer (EORTC QLQ-HDC29) Kim KI11, Kim JH2, Ji EH3, Jang JH4, Kim JS5, Kwon JH6, Kim I7,8,9, Park S7,8,9, Velikova G10, Yoon SS11,12,13, Oh JM14,15.
    View PubMed
  • Ann Hematol. 2016 Mar;95(4):625-35. doi: 10.1007/s00277-015-2580-z. Epub 2015 Dec 22. Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML Ahn JS11, Kim HJ2, Kim YK1, Jung SH1, Yang DH1, Lee JJ1, Kim NY3, Choi SH3, Jung CW4, Jang JH4, Kim HJ5, Moon JH6, Sohn SK6, Won JH7, Kim SH8, Kim DD9.
    View PubMed
  • J Korean Med Sci. 2016 Feb;31(2):214-21. doi: 10.3346/jkms.2016.31.2.214. Epub 2016 Jan 26. Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry Jang JH11, Kim JS2, Yoon SS3, Lee JH4, Kim YK5, Jo DY6, Chung J7, Sohn SK8, Lee JW9.
    View PubMed
  • Future Oncol. 2016 Feb;12(3):293-302. doi: 10.2217/fon.15.326. Epub 2016 Jan 19. Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia Roboz GJ11, Montesinos P2, Selleslag D3, Wei A4, Jang JH5, Falantes J6, Voso MT7, Sayar H8, Porkka K9, Marlton P10, Almeida A11, Mohan S12, Ravandi F13, Garcia-Manero G13, Skikne B14, Kantarjian H13.
    View PubMed
  • Ann Hematol. 2016 Jan;95(2):325-35. doi: 10.1007/s00277-015-2523-8. Epub 2015 Oct 10. Clinical significance of bone marrow hemophagocytosis in adult patients with malignancy and non-malignancy-induced hemophagocytic lymphohistiocytosis Lim SH11, Park S1, Jang JH1, Kim K1, Kim HJ2, Kim SH2, Kang CI3, Chung DR3, Peck KR3, Lee J4, Cha HS4, Koh EM4, Ko YH5, Kim WS1, Jung CW1, Kim SJ6,7.
    View PubMed
  • Ann Hematol. 2016 Jan;95(1):125-33. doi: 10.1007/s00277-015-2511-z. Epub 2015 Sep 29. Distinct subgroups of paroxysmal nocturnal hemoglobinuria (PNH) with cytopenia: results from South Korean National PNH Registry Kim JS11, Jang JH2, Yoon SS3, Lee JH4, Kim YK5, Jo DY6, Chung JS7, Sohn SK8, Lee JW9.
    View PubMed
  • Biol Blood Marrow Transplant. 2016 Jan;22(1):61-70. doi: 10.1016/j.bbmt.2015.07.030. Epub 2015 Jul 31. DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation Ahn JS11, Kim HJ2, Kim YK1, Lee SS1, Jung SH1, Yang DH1, Lee JJ1, Kim NY3, Choi SH3, Jung CW4, Jang JH4, Kim HJ5, Moon JH6, Sohn SK6, Won JH7, Kim SH8, Kim DD9.
    View PubMed
  • Ann Hematol. 2016 Jan;95(2):337-44. doi: 10.1007/s00277-015-2545-2. Epub 2015 Nov 24. Efficacy and safety of micafungin versus intravenous itraconazole as empirical antifungal therapy for febrile neutropenic patients with hematological malignancies: a randomized, controlled, prospective, multicenter study Jeong SH11, Kim DY2, Jang JH3, Mun YC4, Choi CW5, Kim SH6, Kim JS7, Park JS8.
    View PubMed
  • Int J Hematol. 2016 Jan;103(1):44-52. doi: 10.1007/s12185-015-1889-7. Epub 2015 Oct 28. Multicenter, prospective study to evaluate the efficacy of biweekly romiplostim administration in patients with immune thrombocytopenia Park S11, Yoon SS2, Lee JH3, Park JS4, Jang JH5, Lee JW6.
    View PubMed
  • Ann Hematol. 2016 Jan;95(2):301-10. doi: 10.1007/s00277-015-2540-7. Epub 2015 Nov 4. Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant Ahn JS11, Kim JY1, Kim HJ2, Kim YK1, Lee SS1, Jung SH1, Yang DH1, Lee JJ1, Kim NY3, Choi SH3, Minden MD4, Jung CW5, Jang JH5, Kim HJ6, Moon JH7, Sohn SK7, Won JH8, Kim SH9, Kim DD4.
    View PubMed
  • Oncotarget. 2015 Dec 29;6(42):44985-94. doi: 10.18632/oncotarget.6242. A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome Jeong SH11, Kim YJ2, Lee JH3, Kim YK4, Kim SJ5, Park SK6, Do YR7, Kim I8, Mun YC9, Kim HG10, Lee WS11, Yi HG12, Joo YD13, Choi CW14, Kim SR15, Na SM15, Jang JH16.
    View PubMed
  • Oncotarget. 2015 Dec 15;6(40):42803-12. doi: 10.18632/oncotarget.5658. Iron deficient erythropoiesis might play key role in development of anemia in cancer patients Park S11, Jung CW1, Kim K1, Kim SJ1, Kim WS1, Jang JH1.
    View PubMed
  • Liver Int. 2015 Nov;35(11):2363-9. doi: 10.1111/liv.12838. Epub 2015 Apr 12. Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy Lee JY11, Lim SH1, Lee MY1, Kim H1, Sinn DH1, Gwak GY1, Choi MS1, Lee JH1, Jung CW1, Jang JH1, Kim WS1, Kim SJ1, Kim K1.
    View PubMed
  • Int J Hematol. 2015 Oct;102(4):401-12. doi: 10.1007/s12185-015-1862-5. Epub 2015 Sep 1. A randomized controlled trial comparing darbepoetin alfa doses in red blood cell transfusion-dependent patients with low- or intermediate-1 risk myelodysplastic syndromes Jang JH11, Harada H2,3, Shibayama H4, Shimazaki R5, Kim HJ6, Sawada K7, Mitani K8.
    View PubMed
  • Lancet Haematol. 2015 Oct;2(10):e417-26. doi: 10.1016/S2352-3026(15)00149-0. Epub 2015 Oct 1. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial Platzbecker U11, Wong RS2, Verma A3, Abboud C4, Araujo S5, Chiou TJ6, Feigert J7, Yeh SP8, Gotze K9, Gorin NC10, Greenberg P11, Kambhampati S12, Kim YJ13, Lee JH14, Lyons R15, Ruggeri M16, Santini V17, Cheng G18, Jang JH19, Chen CY20, Johnson B21, Bennett J22, Mannino F23, Kamel YM24, Stone N23, Dougherty S23, Chan G23, Giagounidis A25.
    View PubMed
  • Blood Cancer J. 2015 Oct 16;5:e358. doi: 10.1038/bcj.2015.84. Single monosomy as a relatively better survival factor in acute myeloid leukemia patients with monosomal karyotype Jang JE11, Min YH1, Yoon J2, Kim I3, Lee JH4, Jung CW5, Shin HJ6, Lee WS7, Lee JH8, Hong DS9, Kim HJ10, Kim HJ2, Park S3, Lee KH4, Jang JH5, Chung JS6, Lee SM7, Park J8, Park SK9, Ahn JS10, Min WS2, Cheong JW1; Korean Society of Hematology AML/MDS Working Party.
    View PubMed
  • Transpl Infect Dis. 2015 Oct;17(5):679-87. doi: 10.1111/tid.12424. Epub 2015 Sep 26. Incidence of infection according to intravenous immunoglobulin use in autologous hematopoietic stem cell transplant recipients with multiple myeloma Park S11, Jung CW1, Jang JH1, Kim SJ1, Kim WS1, Kim K1.
    View PubMed
  • Haematologica. 2015 Sep;100(9):e351-3. doi: 10.3324/haematol.2015.126227. Epub 2015 Jun 4. Adverse prognostic effect of homozygous TET2 mutation on the relapse risk of acute myeloid leukemia in patients of normal karyotype Ahn JS11, Kim HJ2, Kim YK1, Jung SH1, Yang DH1, Lee JJ1, Lee IK3, Kim NY3, Minden MD4, Jung CW5, Jang JH5, Kim HJ6, Moon JH7, Sohn SK7, Won JH8, Kim SH9, Kim N10, Yoshida K11, Ogawa S11, Kim DD4.
    View PubMed
  • Hum Immunol. 2015 Sep;76(9):636-43. doi: 10.1016/j.humimm.2015.09.009. Epub 2015 Sep 25. KIR alloreactivity based on the receptor-ligand model is associated with improved clinical outcomes of allogeneic hematopoietic stem cell transplantation: Result of single center prospective study Park S11, Kim K1, Jang JH1, Kim SJ1, Kim WS1, Kang ES2, Jung CW3.
    View PubMed
  • Blood. 2015 Jul 16;126(3):291-9. doi: 10.1182/blood-2015-01-621664. Epub 2015 May 18. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts Dombret H11, Seymour JF2, Butrym A3, Wierzbowska A4, Selleslag D5, Jang JH6, Kumar R7, Cavenagh J8, Schuh AC9, Candoni A10, Recher C11, Sandhu I12, Bernal del Castillo T13, Al-Ali HK14, Martinelli G15, Falantes J16, Noppeney R17, Stone RM18, Minden MD9, McIntyre H19, Songer S19, Lucy LM19, Beach CL19, Dohner H20.
    View PubMed
  • Oncotarget. 2015 Jun 30;6(18):16653-62. Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients Jung HA11,2, Maeng CH3, Kim M1, Kim S1, Jung CW1, Jang JH1.
    View PubMed
  • Acta Haematol. 2015;134(1):40-8. doi: 10.1159/000368711. Epub 2015 Jun 6. Azacitidine Pre-Treatment Followed by Reduced-Intensity Stem Cell Transplantation in Patients with Higher-Risk Myelodysplastic Syndrome Ahn JS11, Kim YK, Min YH, Cheong JW, Jang JH, Jung CW, Kim IH, Yoon HJ, Lee HG, Sohn SK, Moon JH, Kim H, Kim YJ, Won JH, Chung JS, Mun YC, Lee JH, Kim HJ.
    View PubMed
  • Leuk Lymphoma. 2015 May;56(5):1550-1. doi: 10.3109/10428194.2014.971408. Epub 2014 Nov 3. A case of CD5-positive mature B-cell neoplasm with t(10;14)(q24;q11.2) and trisomy 12 Shin SY11, Lee ST, Kim HJ, Jang JH, Jung CW, Kim SH.
    View PubMed
  • Anticancer Res. 2015 May;35(5):3081-9. Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome Hong JY11, Seo JY2, Kim SH3, Jung HA4, Park S4, Kim K4, Jung CW4, Kim JS5, Park JS6, Kim HJ7, Jang JH8.
    View PubMed
  • J Clin Oncol. 2015 Apr 10;33(11):1252-7. doi: 10.1200/JCO.2014.57.0952. Epub 2015 Mar 2. Phase III Open-Label Randomized Study of Cytarabine in Combination With Amonafide L-Malate or Daunorubicin As Induction Therapy for Patients With Secondary Acute Myeloid Leukemia Stone RM11, Mazzola E2, Neuberg D2, Allen SL2, Pigneux A2, Stuart RK2, Wetzler M2, Rizzieri D2, Erba HP2, Damon L2, Jang JH2, Tallman MS2, Warzocha K2, Masszi T2, Sekeres MA2, Egyed M2, Horst HA2, Selleslag D2, Solomon SR2, Venugopal P2, Lundberg AS2, Powell B2.
    View PubMed
  • Ann Lab Med. 2015 Jan;35(1):159-61. doi: 10.3343/alm.2015.35.1.159. Epub 2014 Dec 8. Two Cases of Acute Lymphoblastic Leukemia with an ela3 BCR-ABL1 Fusion Transcript Shin SY11, Cho JH1, Kim HJ1, Jang JH2, Lee ST1, Kim SH1.
    View PubMed
  • Tissue Antigens. 2014 Dec;84(6):582-3. doi: 10.1111/tan.12435. Epub 2014 Oct 10. A new HLA-A*30 allele, A*30:81, identified by sequence-based typing Yoon YA11, Kim JS, Yoon CE, Jang JH, Kang ES.
    View PubMed
  • Vox Sang. 2014 Nov;107(4):407-15. doi: 10.1111/vox.12183. Epub 2014 Jul 31. Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience Lee KH11, Jung SK, Kim SJ, Jang JH, Kim K, Kim WS, Jung CW, Kim DW, Kang ES.
    View PubMed
  • Leuk Lymphoma. 2014 Oct;55(10):2395-7. doi: 10.3109/10428194.2014.880429. Epub 2014 Mar 7. Spinal cord compression in multiple myeloma: a single center experience Jung HA11, Cho SH, Kim SJ, Jang JH, Kim WS, Jung CW, Kim K.
    View PubMed
  • Anticancer Res. 2014 Aug;34(8):4299-306. Renal Insufficiency in Newly-diagnosed Multiple Myeloma: Analysis According to International Myeloma Working Group Consensus Statement Park S11, Han B2, Kim K3, Kim SJ1, Jang JH1, Kim WS1, Jung CW1.
    View PubMed
  • Biomed Res Int. 2014;2014:437852. doi: 10.1155/2014/437852. Epub 2014 Jul 10. Comparison of the Freiburg and Charlson Comorbidity Indices in Predicting Overall Survival in Elderly Patients with Newly Diagnosed Multiple Myeloma Kim SM11, Kim MJ1, Jung HA1, Kim K1, Kim SJ1, Jang JH1, Kim WS1, Jung CW1.
    View PubMed
  • Ann Hematol. 2014 Jun;93(6):931-5. doi: 10.1007/s00277-014-2006-3. Epub 2014 Jan 31. Hereditary gene mutations in Korean patients with isolated erythrocytosis Jang JH11, Seo JY, Jang J, Jung CW, Lee KO, Kim SH, Kim HJ.
    View PubMed
  • Acta Haematol. 2014;131(4):193-9. doi: 10.1159/000354839. Epub 2013 Nov 26. Positive Correlation between Baseline PET or PET/CT Findings and Clinical Parameters in Multiple Myeloma Patients Park S11, Lee SJ, Chang WJ, Maeng CH, Hong JY, Choi MK, Kim YS, Jung CW, Jang JH, Kim SJ, Kim WS, Choi JY, Kim K.
    View PubMed
  • Int J Hematol. 2014;99(5):635-43. doi: 10.1007/s12185-014-1549-3. Epub 2014 Mar 20. Multicenter study evaluating the impact of hypomethylating agents as bridging therapy to hematopoietic stem cell transplantation in myelodysplastic syndromes Kim Y11, Kim IH, Kim HJ, Park S, Lee KH, Kim SJ, Lee JH, Kim DY, Yoon SS, Kim YK, Jang JH, Park SY, Ahn JS, Cheong CW, Lee JH, Cheong JW; Korean Society of Hematology Acute myeloid Leukemia/Myelodysplastic Syndrome Working Party.
    View PubMed
  • Ann Hematol.?2014 Apr;93(4):603-8. doi: 10.1007/s00277-013-1915-x. Epub 2013 Oct 19. Clinical significance of SF3B1 mutations in Korean patients with myelodysplastic syndromes and myelodysplasia/myeloproliferative neoplasms with ring sideroblasts Seo JY11,?Lee KO,?Kim SH,?Kim K,?Jung CW,?Jang JH,?Kim HJ.
    View PubMed
  • Anticancer Res. 2014 Feb;34(2):1037-45. Prognostic Factor Analysis in Core-Binding Factor-positive Acute Myeloid Leukemia Jung HA11, Maeng CH, Park S, Kim SJ, Kim K, Jang JH, Jung CW.
    View PubMed
  • J Korean Med Sci. 2014 Jan;29(1):61-8. doi: 10.3346/jkms.2014.29.1.61. Epub 2013 Dec 26. Success Rate and Risk Factors for Failure of Empirical Antifungal Therapy with Itraconazole in Patients with Hematological Malignancies: A Multicenter, Prospective, Open-Label, Observational Study in Korea Kim SJ11, Cheong JW1, Min YH1, Choi YJ2, Lee DG3, Lee JH4, Yang DH5, Lee SM6, Kim SH7, Kim YS8, Kwak JY9, Park J10, Kim JY11, Kim HG12, Kim BS13, Ryoo HM14, Jang JH15, Kim MK16, Kang HJ17, Cho IS18, Mun YC19, Jo DY20, Kim HY21, Park BB22, Kim JS1.
    View PubMed
  • Ann Hematol. 2014 Jan;93(1):99-105. doi: 10.1007/s00277-013-1952-5. Epub 2013 Nov 16. DCEP for relapsed or refractory multiple myeloma after therapy with novel agents Park S11, Lee SJ, Jung CW, Jang JH, Kim SJ, Kim WS, Kim K.
    View PubMed
  • J?Korean?Med Sci.?2013 Nov;28(11):1563-72. doi: 10.3346/jkms.2013.28.11.1563. Epub 2013 Oct 31. Korean Guideline for Iron Chelation Therapy in Transfusion-Induced Iron Overload Jang JH11,?Lee JH,?Yoon SS,?Jo DY,?Kim HJ,?Chung J,?Lee JW;?Korean?Society of Hematology Aplastic Anemia Working Party.
    View PubMed
  • Int J Hematol.?2013 Jun;97(6):749-57. doi: 10.1007/s12185-013-1346-4. Epub 2013 May 1. Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry Lee JW11,?Jang JH,?Kim JS,?Yoon SS,?Lee JH,?Kim YK,?Jo DY,?Chung J,?Sohn SK.
    View PubMed
  • Am J Hematol. 2012 Jan;87(1):37-41. doi: 10.1002/ajh.22193. Epub 2011 Nov 25. Monosomal karyotype in acute myeloid leukemia predicts adverse treatment outcome and associates with high functional multidrug resistance activity Ahn HK11, Jang JH, Kim K, Kim HJ, Kim SH, Jung CW, Kim DH.
    View PubMed
  • Haematologica.?2011 Oct;96(10):1441-7. doi: 10.3324/haematol.2011.046078. Epub 2011 Jun 9. A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome Lee JH11,?Jang JH,?Park J,?Park S,?Joo YD,?Kim YK,?Kim HG,?Choi CW,?Kim SH,?Park SK,?Park E,?Min YH.
    View PubMed
  • Clin Lymphoma Myeloma Leuk.?2011 Jun;11(3):273-9. doi: 10.1016/j.clml.2011.03.015. Epub 2011 Apr 20. External Validation of Newly Proposed Cytogenetic Risk Classification in Patients Who Have Myelodysplastic Syndrome: A Retrospective Analysis at a Single Institution Yun J11,?Kim DH,?Kong JH,?Kim HJ,?Kim SH,?Kim K,?Jang JH,?Jung CW.
    View PubMed
  • Transplant Proc.?2010 Nov;42(9):3723-8. doi: 10.1016/j.transproceed.2010.09.005. Feasibility of Second Hematopoietic Stem Cell Transplantation Using Reduced-Intensity Conditioning with Fludarabine and Melphalan after a Failed Autologous Hematopoietic Stem Cell Transplantation Hong JY11,?Choi MK,?Kim DH,?Kim SJ,?Kim K,?Kim WS,?Chung CW,?Kim HO,?Min YH,?Jang JH.
    View PubMed
  • Leuk Lymphoma.?2010 Dec;51(12):2250-7. doi: 10.3109/10428194.2010.524324. Epub 2010 Oct 7. Decitabine in myelodysplastic syndromes and chronic myelomonocytic leukemia: Argentinian/South Korean multi-institutional clinical experience Iastrebner M11,?Jang JH,?Nucifora E,?Kim K,?Sackmann F,?Kim DH,?Orlando S,?Jung CW,?Basquiera A,?Klein G,?Santini F,?Bernard HI,?Korin J,?Taborda G.
    View PubMed
  • Acta Haematol.?2010;124(2):92-7. doi: 10.1159/000315558. Epub 2010 Jul 21. Efficacy and Safety of Micafungin as an Empirical Antifungal Agent for Febrile Neutropenic Patients with Hematological Diseases Park JS11,?Kim DH,?Choi CW,?Jeong SH,?Choi JH,?Kim K,?Kim SJ,?Jung CW,?Yang DH,?Jang JH.
    View PubMed
  • Int J Hematol. 2010 Jun;91(5):886-91. doi: 10.1007/s12185-010-0580-2. Epub 2010 May 8. A randomized trial of preemptive therapy for prevention of cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation Kim ST11, Lee MH, Kim SY, Kim SJ, Kim DH, Jang JH, Kim K, Kim WS, Jung CW.
    View PubMed
  • J Clin Oncol. 2010 Feb 1;28(4):e54-5. doi: 10.1200/JCO.2009.23.7560. Epub 2009 Nov 16. Gastric Recurrence of Extramedullary Granulocytic Sarcoma After Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia Choi ER11, Ko YH, Kim SJ, Jang JH, Kim K, Kang WK, Jung CW, Kim DH.
    View PubMed
  • Leuk Res. 2010 Feb;34(2):166-72. doi: 10.1016/j.leukres.2009.05.009. Epub 2009 Jun 10. BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients Moon JH11, Sohn SK, Lee MH, Jang JH, Kim K, Jung CW, Kim DH.
    View PubMed
  • Eur J Haematol.?2008 Nov;81(5):364-73. doi: 10.1111/j.1600-0609.2008.01124.x. Epub 2008 Jul 10. Is International Prognostic Scoring System (IPSS) still standard in predicting prognosis in patients with myelodysplastic syndrome External validation of the WHO Classification-Based Prognostic Scoring System (WPSS) and comparison with IPSS Park MJ11,?Kim HJ,?Kim SH,?Kim DH,?Kim SJ,?Jang JH,?Kim K,?Kim WS,?Jung CW.
    View PubMed